Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer


Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.

In an interview with CancerNetwork® during the The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Anjali Y. Hari, MD, an obstetrician-gynecologist at the University of California (UC), Irvine, School of Medicine, discussed the rationale for and key findings from assessing hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.

Both groups were reported to have generally similar outcomes, including both intraoperatively and postoperatively as well as with regard to survival, Hari explained. Notably, the frail population received carboplatin and the non-frail population was treated with cisplatin.


HIPEC is still a widely debated topic in ovarian cancer, but it is included in the NCCN guidelines now. We wanted to look at our outcomes at UC, Los Angeles; UC, Irvine; and UC, San Diego. It can be a highly toxic treatment, so we wanted to look and see if there were differences in patients who we considered frail vs non frail in terms of tolerating it.

The majority [of patients had] stage III epithelial ovarian cancer [and] high-grade serous histology. The majority had 3 cycles of neoadjuvant chemotherapy followed by interval cytoreductive surgery.

The patients did very similarly intraoperatively, postoperatively, and with survival outcomes. The only significant finding that we had was that [in] frail patients, the agent that we used during HIPEC was more commonly carboplatin vs in non-frail patients, the more commonly used agent was cisplatin. [In a trial] that came out through Europe, the agent that was used was cisplatin. The NCCN guidelines also mentioned cisplatin, but it can be more nephrotoxic. [Therefore], it was interesting to see that in frail patients, carboplatin was more commonly used.


Hari A, Furey K, Jou J, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) outcomes across 3 academic institutions among frail and non-frail patients. Presented at: Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer. March 18-21, 2022. Phoenix, AZ.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.